BiotechTube
Diakonos Oncology

Diakonos Oncology

Houston, United States· Est.
diakonosoncology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Diakonos Oncology is pioneering a novel dendritic cell vaccine (DCV) platform based on a discovery of a new immunological pathway. Its lead program, DOC1021, is in Phase 2 trials for glioblastoma (GBM) and Phase 1 for pancreatic adenocarcinoma, showing promising early results. The company, which operates as a private entity, leverages research from the Texas Medical Center and collaborates with leading institutions like Baylor College of Medicine and MD Anderson. Its approach focuses on addressing critical unmet needs in aggressive, late-stage cancers with poor prognoses.

Oncology

Technology Platform

Proprietary dendritic cell vaccine (DCV) platform featuring a 'double-loading' technique that presents tumor antigens on both MHC Class I and II. This mimics a viral infection, harnessing the body's anti-viral immune response (specifically CD8+ CD161+ T cells) to attack cancer cells.

Funding History

2
Series AUndisclosed
SeedUndisclosed

Opportunities

The primary opportunity lies in addressing massive unmet needs in glioblastoma and pancreatic cancer, two lethal cancers with poor survival rates and multi-billion dollar market potential.
Positive clinical data could lead to accelerated regulatory pathways, strategic partnerships, or acquisition interest.
The platform technology also has potential for expansion into other solid tumor indications.

Risk Factors

High risk of clinical trial failure in notoriously difficult-to-treat cancers.
Financial risk due to dependence on external funding to advance costly clinical programs.
Competitive risk from numerous other immuno-oncology approaches.
Scalability and manufacturing challenges associated with autologous cell therapy.

Competitive Landscape

Diakonos competes in the crowded immuno-oncology space against other cell therapies (e.g., CAR-T), cancer vaccines, bispecific antibodies, and checkpoint inhibitors. Its direct competitors include other dendritic cell vaccine developers and companies targeting GBM/pancreatic cancer. Differentiation hinges on its unique 'double-loading' mechanism aiming to generate a more potent, virus-like immune response.

More companies in Cell & Gene Therapy →More companies in United States →